Navigation Links
ADVENTRX Announces Completion of Patient Enrollment in ANX-530 Marketing-Enabling Clinical Study
Date:10/10/2007

SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that it has completed patient enrollment in its marketing-enabling clinical study of ANX-530 (vinorelbine emulsion), a novel, emulsion formulation of vinorelbine tartrate. Vinorelbine tartrate, marketed under the brand name Navelbine(R), is an anti-cancer agent that is approved to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin. Worldwide annual sales of Navelbine and generic vinorelbine in 2006 were approximately $200 million.

"Completing enrollment keeps us on schedule to announce results from this study next month and, if the results are succesful, to submit an NDA as early as next year," said Evan M. Levine, chief executive officer of ADVENTRX. "Advancing ANX-530 is a key value-driver for this company and we are taking the steps to help ensure its success. We are preparing for a meeting with the FDA later this year and plan to provide an update regarding our NDA timeline for ANX-530 following that meeting."

ANX-530 is currently being tested in a 28-patient bioequivalence study. The study is a crossover comparison of ANX-530 and Navelbine, also available as generic vinorelbine, with a primary endpoint of pharmacokinetic equivalence of ANX-530 and Navelbine. The safety of a single dose of ANX-530 is being evaluated as a secondary endpoint. The FDA has indicated that this single clinical study, should it demonstrate bioequivalence between ANX-530 and Navelbine, would provide sufficient clinical dat
'/>"/>

SOURCE ADVENTRX Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. Adventrx Announces Positive Data From Multidrug Therapy With CoFactor
3. ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2008)...lington Medical Resources (AMR), a,provider of pr...nd diagnostic,imaging industries, finds that over...n the U.S. during the third quarter of 2008. Privi...bulin (IVIG) and was launched in the first,quarte...d plasma of thousands,of donors and is used to tr...
(Date:11/18/2008)...f Influenza survey underscores that mothers need t... and Gold Medalist Kristi Yamaguchi joins initiati... While 78 percent of mothers in the United States ...hreatening disease that can strike anyone, only ha...ated this season, according to a new survey from t...
(Date:11/13/2008)...FirstCall/ -- Hologic, Inc.,(Nasdaq: HOLX ), a le...ium,diagnostics, medical imaging systems and surgi...eeds of women, today announced the results of the,... Cervista HPV high-risk,test is currently under re...launched in the European Union (EU) early in 2009....
(Date:11/13/2008)...s Cut Risk of Heart Attacks, Deaths, RESTON, Va.,... Disease,is the leading cause of death among Ameri...llions of dollars and causing untold suffering. No...ase - even among those who,weren,t thought to be a...eople could cut their risk of a,heart attack, stro...
Breaking Medicine Technology:Over $10 Million of CSL Behring's Privigen Was Sold in the U.S. During the Third Quarter of 2008 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 2Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 3Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials 4Seniors Can Be Heartened by New Study on Statins 2Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 1Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 7665 2Dads break bones of children more often than moms 7663 1Dads break bones of children more often than moms 7663 2FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 1FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 2FDA Panel Says No to Avastin for Advanced Breast Cancer 7661 3Scientists identify gene that influences alcohol consumption 7659 1Scientists identify gene that influences alcohol consumption 7659 2
...--(BUSINESS WIRE)--Apr 13, 2007 - Ascenta Therapeu... portfolio of,apoptosis-triggering compounds will ...l poster presentations at next week,s 2007,Annual ...earch,(AACR), to be held in Los Angeles, Californi...een selected for presentation at the,"High Impact ...
...ITY, April 13, 2007 /PRNewswire-FirstCall/ - AEter...utical company,focused on endocrine therapy and on...bstracts outlining first in vitro data on its,PI3K...tagonist,JMR-132, which both may potentially prov...f cancer. These abstracts will be,presented at the...
Other Medicine Technology:Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 2Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 3Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 4Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 5Ascenta Therapeutics Highlights Multiple Data Presentations at,Upcoming AACR Annual Meeting 6AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 2AEterna Zentaris To Present First In Vitro Data for PI3K Inhibitors,and In Vivo Results for a GHRH Antagonist at the AACR Annual,Meeting in Los Angeles 3
(Date:11/21/2008)...e/ -- In a statewide survey, 33 physicians credent...ry at Presbyterian Hospital of Dallas were honored..." Super Doctors ." , , Each year, the publi...l Media, Inc. to survey more than 38,000 medical p... you needed medical care, which doctor would you c...
(Date:11/21/2008)...1 A prestigious group of physician...ther in Williamsburg, VA on March 27-29, 2009 at t... information on cutting-edge therapeutic protocols...arch advances that impact patient care. The full p...nformation is available at www.bioconferences.com...
(Date:11/21/2008)...e/ -- Innerscope Research(TM), a revolutionary,bi...nal Response Measurement,announced today the app...he,company,s research and development, business s...hree appointments, who deliver a combined 60 years...nancial Officer and Vice President of,Strategy; D...
(Date:11/21/2008)...The University of Texas M. D. Anderson Cancer Cent...to eradicate breast cancer in Panama through the P...h of the Americas today at an event with Laura Bus... Fernndez de Torrijos, the First Lady of Panama. ...the U.S. Department of State and Susan G. Komen fo...
Breaking Medicine News(10 mins):Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2Health News:17th Annual Congress on Women's Health Convenes March 27-29, 2009 in Williamsburg, VA 2Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:First Lady Laura Bush's Partnership for Breast Cancer Awareness and Research extends to Panama 2
...view that was published in the Friday’s issue of t... kids does not reduce their risk of fractures in t...of the maximum bone mass is got by the age of 18 y...ing bone mass at an early age might reduce the eff...
...to have developed a technique to find out if metas... liver.// <br.The research scientists at Wash...have developed a test for the prediction of whethe...r, where it could quickly transform into being ver...
... 'Raloxifene' can reduce postmenopausal women with...new study that has been published in the September... could protect postmenopausal women from developin... whether they are at high or low risk of developin...
...der, generation or income group, more and more peo...sus a gym and an exercise physiologist// at New Yo...center for sports medicine, thinks she knows why. ...t is safe, balanced, promotes fitness and importan...
Other Medicine News:Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 2Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 3Health News:Metastasis Of Ocular Melanoma To Liver Can Now Be Calculated 4Health News:Raloxifene Reduces The Risk Of Breast Cancer 2Health News:Raloxifene Reduces The Risk Of Breast Cancer 3Health News:Dance Your Way to a Better Body 2Health News:Dance Your Way to a Better Body 3
...cal IOL is a foldable silicone IOL. It features a ...e inserted with The UNFOLDER® Silver-T Implant... first and only FDA-approved multifocal IOL, and t...nal visionnear, intermediate, and far. The ARRAY&r...
...ferred viscoelastic for phacoemulsification proced...rks from the start to the finish of the case. The ...lastic is the reason. The low to moderate vacuum f...nly a fraction of the viscoelastic agent. However,...
...scoelastic agent for the surgeon who performs cata... Amvisc possesses sufficient viscosity for excelle... is highly cohesive so that complete removal at th...ed. Amvisc is priced to compete with any sodium hy...
...onate (1.8%) viscoelastic solution combines maximu...flo maintains a deep anterior chamber and protects... ideal for routine cataract surgery but can be use...lastic. Combine all these properties with the conv...
Medicine Products: